Abstract C186: A glycoengineered anti-CD19 antibody (MEDI-551) is effective as monotherapy or in combination treatment in mouse models of B-cell malignancies
Lists
Only you see this
Abstract
Abstract Human cluster of differentiation (CD) antigen 19 is a B cell-specific surface antigen that is expressed by early pre-B cells and throughout B cell differentiation until it is down-regulated during terminal differentiation of plasma cells. Expression of CD19 is maintained following malignant transformation and therefore CD19 is expressed on the majority of B cell-derived leukemias and lymphomas. MEDI-551 is a humanized immunoglobulin G1 kappa (IgG1) monoclonal antibody (MAb) directed against CD19. The Fc portion of MEDI-551 does not contain a fucose sugar moiety due to its expression in BioWa's Potelligent® cells. This afucosylated form of MEDI-551 exhibits enhanced CD16 binding and antibody-dependent cellular cytotoxicity (ADCC). Rituximab, another B-cell targeted therapy, is directed against CD20 and is widely used for the treatment of B cell malignancies. However, a subset of patients is unresponsive to rituximab therapy and the majority of patients will relapse following treatment. We have previously shown that the glycoengineered, ADCC-enhanced anti-CD19 MAb is effective in in vitro and in vivo models of B cell leukemia and lymphoma. The purpose of the present study was to explore the anti-tumor activity of the anti-CD19 MAb in SCID mouse models of human lymphoma as single agent and in combination with rituximab. In several models the combination of anti-CD19 with anti-CD20 resulted in prolonged suppression of tumor growth with no untoward adverse events observed. The results suggest that combination therapy targeting both CD19 and CD20 could be an effective approach in the clinic for the treatment of B cell lymphomas. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):C186.
BibTeX
@inproceedings{ward2009abstract,
author = {Beth K. Ward and Nanette Mittereder and Ellen Kuta and Gary P. Sims and M Damschroeder and William F. Dall’Acqua and Michael A. Bowen and Hongbing Wu and Thomas F. Tedder and Peter A. Kiener and Bahija Jallal and Thomas Coyle and Ronald Herbst},
title = {{Abstract C186: A glycoengineered anti-CD19 antibody (MEDI-551) is effective as monotherapy or in combination treatment in mouse models of B-cell malignancies}},
booktitle = {Molecular},
year = {2009},
doi = {10.1158/1535-7163.targ-09-c186},
}Loading related content...